OS Therapies: OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
OS Therapies (NYSE American: OSTX) said it will publish four Drug Discovery World articles on OST-HER2 and osteosarcoma. The company also reiterated it will present 2.5-year overall survival data from its Phase 2b OST-HER2 trial at the 2026 ASCO Annual Meeting (May 28–June 2, 2026). It is seeking a U.S. BLA under Accelerated Approval in 2H 2026.
How this was made
The 30-second read
Why it matters
The key tradable element is the scheduled 2.5-year overall survival data release at ASCO, which can shift expectations for durability of benefit and strengthen the regulatory case.
Market read
Sets a concrete upcoming clinical-data catalyst for OSTX tied to a lead program and survival durability, likely influencing positioning into ASCO.
What to watch
BLA/Accelerated Approval timing and PRV monetization depend on FDA review outcomes; any mismatch between event-free survival and longer-term OS could temper the enthusiasm.
Background
OS Therapies is advancing OST-HER2, a listeria-based immunotherapy targeting HER2 epitopes, with multiple FDA/EMA designations and plans for BLA/accelerated approval in 2026.
Ticker impact
OS Therapies (OSTX) reiterated it will release 2.5-year overall survival data from Phase 2b OST-HER2 at the 2026 ASCO Annual Meeting.
Moderate positive bias into ASCO as traders price in the 2.5-year OS datapoint; volatility likely around conference headlines.
The article is a company-specific clinical-catalyst update (OS readout timing) tied to a lead asset and regulatory pathway (BLA/PRV intent). However, it does not provide the actual OS results yet, limiting immediate fundamental surprise.
Market effects
Reinforces investor focus on osteosarcoma immunotherapy and the value of longer-term survival endpoints ahead of regulatory filings.
Primarily US-focused catalyst (ASCO and FDA BLA timing), with downstream EU/UK expectations mentioned.
EMA/UK CMA intentions and PRV eligibility narrative keep global regulatory optionality in view.
Counterpoint
Because the release is only a confirmation of future data (no new efficacy numbers), the market may already be positioned and react more to the actual OS results than to the announcement.
Key entities
- companyOS Therapies, Inc.
Subject of the press release; provides timing for 2.5-year OS data from Phase 2b OST-HER2 and publication updates.
- clinical_programOST-HER2
Lead asset; Phase 2b trial OST-HER2 in fully-resected pulmonary metastatic osteosarcoma with planned 2.5-year OS readout at ASCO.
- eventASCO Annual Meeting 2026
Conference where the company will release the 2.5-year overall survival data.
